Anticarcinogenic impact of interferon on patients with chronic hepatitis C: A large-scale long-term study in a single center

Intervirology

Volumn 49, Issue 1-2, 2006, Pages 82-90

  Ikeda, Kenji ^a   Arase, Yasuji ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Someya, Takashi ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Cirrhosis; Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; BETA INTERFERON; GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; ASCITES; BLEEDING; BRAIN DISEASE; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EYE DISEASE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; JAPAN; JAUNDICE; LEUKOPENIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIVARIATE ANALYSIS; MYALGIA; NEEDLE BIOPSY; PRIORITY JOURNAL; PSYCHOSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 24944442513     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087268     Document Type: Conference Paper

References (33)

1. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
2. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2,215 patients. J Hepatol 1998;28:930-938.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego T: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
4. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
6. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, Unakami M, Morinaga T, Kumada H: Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-1043.
7. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
8. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
9. Schalm SW, Fattovich G, Brouwer JT: Therapy of hepatitis C: Patients with cirrhosis. Hepatology 1997;26:S128-S132.
10. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-909.
11. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D: Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-1695.
12. International Interferon-alpha Hepatocellular Carcinoma Study Group: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539.
13. Hu KQ, Tong MJ: The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-1316.
14. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H: Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 2001;16:406-415.
15. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G: Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
16. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P: Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-1875.
17. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.
18. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
19. Shindo M, Ken A, Okuno T: Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943-1950.
20. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181.
21. Harrington DP, Fleming TR: A class of rank test procedures for censored survival data. Biometrica 1982;69:553-566.
22. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
23. Cox DR: Regression models and life tables. J R Stat Soc 1972;34:248-275.
24. SPSS Incorporation: SPSS for Windows Version 11.0 Manual. Chicago, SPSS Inc., 2001.
25. Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K: Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat 2000;7:343-351.
26. Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Long-term responders without eradication of hepatitis C virus after interferon therapy: Characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000;20:290-295.
27. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1,148 patients. J Hepatol 1999;30:653-659.
28. Moreno MG, Muriel P: Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol 1995;50:515-520.
29. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, Tanabe H, Shimizu A, Yoshida M, Kakita A: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-694.
30. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
31. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
32. Di Bisceglie AM, Carithers RL Jr, Gores GJ: Hepatocellular carcinoma. Hepatology 1998;28:1161-1165.
33. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.